| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 0 | ||||
| Sells | 1 | -350,000 | 100% | $32.25 | -$11,287,500 |
| Net | -1 | -350,000 | -100% | -$11,287,500 |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Mark Lappe | Chief Executive Officer, Director | $15,852,324 | 12 Sep 2024 | ||
| Jon Faiz Kayyem | Director | $15,030,087 | 28 May 2025 | ||
| Brendan P. Eckelman | Chief Scientific Officer | $6,127,372 | 29 May 2024 | ||
| VIKING GLOBAL INVESTORS LP | 10%+ Owner | $3,317,364 | -$11,287,500 | -77% | 07 Oct 2025 |
| DOUGLAS FORSYTH | Director | $3,159,615 | 28 May 2025 | ||
| Kristiina Vuori MD | Director | $306,645 | 28 May 2025 | ||
| KIMBERLY MANHARD | Director | $139,800 | 28 May 2025 | ||
| Inhibrx, Inc. | 10%+ Owner | 29 May 2024 | |||
| David Matly | President | 01 Apr 2025 | |||
| Kelly Deck | Chief Financial Officer | 01 Apr 2025 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|